Adicet Bio, Inc. (ACET)

NCM – Цена в реальном времени. Валюта: USD

8.26

+0.03 (0.36%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

8.26

0.00 (0.00%)

После закрытия: Aug 12, 2026, 4:00 PM EDT

11.08.2026

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Growth Conference.

10.08.2026

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05.08.2026

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2026. “At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional f.

Видео

No Data

There is no data to display

Adicet Bio, Inc. (ACET)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Adicet Bio, Inc. (ACET)

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Adicet Bio, Inc. (ACET)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Adicet Bio, Inc. (ACET)

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Видео

No Data

Пресс-релизы

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates